Gelclair Gelclair (no separate generic/INN name identified; it is a branded formulation) Updated Nov 11
Gelclair is already approved and launched, so the main thing to watch is whether Jaguar's commercial efforts gain traction in the oral mucositis market. The company has shifted strategic focus to rare-disease crofelemer programs (MVID NDA filing targeted mid-2027) and out-licensed its core Mytesi/Canalevia products to Future Pak in January 2026. Gelclair appears to be a smaller part of the portfolio now. The near-term binary catalyst for JAGX is the December 21, 2026 PDUFA for Canalevia (veterinary CID), not Gelclair.
- Gelclair addresses a large addressable market: oral mucositis affects up to 40% of chemotherapy patients and 90% of head and neck cancer patients undergoing radiotherapy, per the National Comprehensive Cancer Network.
- The product is already FDA-approved and generating prescription revenue with no further clinical development risk or regulatory binary ahead.
- Jaguar in-licensed Gelclair through a 5-year exclusive U.S. agreement, providing a commercial foothold in cancer supportive care with an established product.
- Gelclair is a small part of Jaguar's portfolio; the company has publicly shifted focus to rare-disease crofelemer programs and out-licensed its core products, suggesting Gelclair is not a strategic priority.
- Jaguar Health is a micro-cap stock (~$7M market cap) with heavy dilution: recent warrant repricing to $1.00, ELOC floor price reduced to $1.10, and a reverse stock split authorized up to 1:150.
- Minimal institutional interest: only 3 tracked 13F holders as of Q2 2026, with combined holdings of roughly $12,000.